Business
Further investment in Phasefocus Holdings Limited
Further investment in Phasefocus Holdings Limited.
About this update from Truetide Plc
[{"type":"text","content":"\n\n21 August 2023\n \nBraveheart Investment Group Plc\n(\"Braveheart\", the \"Company\" or the \"Group\")\n \nFurther investment in Phasefocus Holdings Limited\n \nBraveheart Investment Group (AIM: BRH), is pleased to announce a further investment into Phasefocus Holdings Limited (\"Phasefocus\"). The Company has purchased 18,750 new ordinary shares of one pence each in Phasefocus at a price of £8 per share for a total consideration of £150,000, taking Braveheart's total interest to 48.3 per cent. of the issued share capital of Phasefocus.\n \nPhasefocus' imaging and analysis system, Livecyte®, uses a novel patented method for high fidelity quantitative imaging and microscopy; this is known in the scientific literature as 'ptychography'.\n \nAs announced on 31 May 2023, Phasefocus has gained substantial momentum during the year and its work, in particular with distributors in Japan, China and the USA, has built a strong pipeline of business opportunities. Phasefocus has received a number of orders for its Livecyte® system, which are scheduled to be delivered before the end of 2023.\nOn 14 August 2023, Phasefocus announced the launch of its revolutionary new T-Cell Killing Assay for the Livecyte® cell imaging platform https://www.phasefocus.com/about/news-events/news/t-cell-assay-announcement. The new assay quantifies interactions between immune cells and cancer cells, addressing a major unmet need for researchers developing the latest novel cancer therapies. In the assay, the characteristics of T cell interactions in the period immediately preceding target cell death, can be measured independently from cytotoxicity. Livecyte's T-Cell Killing Assay offers unparalleled insights at the single-cell level, empowering researchers to unlock new frontiers in cancer therapy development and evaluation.\nThis investment by Braveheart will provide Phasefocus with the working capital to market its new T-Cell Killing Assay and build Livecyte® stock, in preparation for further anticipated orders, and follows a £134,000 investment by the Company into Phasefocus in January 2023.\nIn the year ended 31 December 2022, Phasefocus incurred a loss before taxation of £990,854. The book value of Braveheart's investment in Phasefocus at 31 March 2023 (prior to this investment) was £2.5 million.\n \n \nTrevor Brow...